Keyword: Rare Pediatric Disease Priority Review Voucher

Sarepta sells Exondys 51 PRV to Gilead for $125M

Sarepta has struck a $125 million deal to sell a voucher it got with last year’s controversial FDA approval of its new Duchenne drug to Gilead, which will give the Big Biotech a one-time speedy review pass for an NDA app to the U.S. regulator.